D.Western Therapeutics Institute Inc
TSE:4576
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
D.Western Therapeutics Institute Inc
Other Current Assets
D.Western Therapeutics Institute Inc
Other Current Assets Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Current Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
D
|
D.Western Therapeutics Institute Inc
TSE:4576
|
Other Current Assets
¥128.9m
|
CAGR 3-Years
20%
|
CAGR 5-Years
23%
|
CAGR 10-Years
6%
|
|
|
SanBio Co Ltd
TSE:4592
|
Other Current Assets
¥395.6m
|
CAGR 3-Years
16%
|
CAGR 5-Years
6%
|
CAGR 10-Years
-2%
|
|
|
GNI Group Ltd
TSE:2160
|
Other Current Assets
¥928m
|
CAGR 3-Years
-5%
|
CAGR 5-Years
19%
|
CAGR 10-Years
37%
|
|
|
PeptiDream Inc
TSE:4587
|
Other Current Assets
¥1.1B
|
CAGR 3-Years
28%
|
CAGR 5-Years
25%
|
CAGR 10-Years
27%
|
|
|
Takara Bio Inc
TSE:4974
|
Other Current Assets
¥1.9B
|
CAGR 3-Years
-3%
|
CAGR 5-Years
20%
|
CAGR 10-Years
4%
|
|
|
O
|
Oncolys Biopharma Inc
TSE:4588
|
Other Current Assets
¥395.3m
|
CAGR 3-Years
-11%
|
CAGR 5-Years
6%
|
CAGR 10-Years
30%
|
|
D.Western Therapeutics Institute Inc
Glance View
D. Western Therapeutics Institute, Inc. engages in the research and development of pharmaceutical drugs. The company is headquartered in Nagoya, Aichi-Ken and currently employs 19 full-time employees. The company went IPO on 2009-10-23. The firm generates revenue from licensing of its developed drugs to other companies. As of December 31, 2012, the Company’s drug pipeline included anti-thrombotic medicine K-134, therapeutic agent K-115 for glaucoma, and anticancer drug HMN-214. Its newly-developed products include new anti-thrombotic medicine and signal-transduction inhibitors, including therapeutic agent for high-blood pressure, protective agent for nerves, therapeutic agent for atherosclerosis, ophthalmologic drug and anticancer drug, among others. The firm is also developing new drug candidate compounds focusing on protein kinase inhibitors and involving in ophthalmic surgical adjuvant business, which includes ingredient of Brilliant Blue G-250.
See Also
What is D.Western Therapeutics Institute Inc's Other Current Assets?
Other Current Assets
128.9m
JPY
Based on the financial report for Dec 31, 2025, D.Western Therapeutics Institute Inc's Other Current Assets amounts to 128.9m JPY.
What is D.Western Therapeutics Institute Inc's Other Current Assets growth rate?
Other Current Assets CAGR 10Y
6%
Over the last year, the Other Current Assets growth was 5%. The average annual Other Current Assets growth rates for D.Western Therapeutics Institute Inc have been 20% over the past three years , 23% over the past five years , and 6% over the past ten years .
